MARKET

ALPN

ALPN

Alpine Immune Sc
NASDAQ
64.64
+0.04
+0.06%
After Hours: 64.60 -0.04 -0.06% 16:44 05/07 EDT
OPEN
64.60
PREV CLOSE
64.60
HIGH
64.67
LOW
64.56
VOLUME
1.33M
TURNOVER
0
52 WEEK HIGH
64.72
52 WEEK LOW
6.71
MARKET CAP
4.24B
P/E (TTM)
-100.4195
1D
5D
1M
3M
1Y
5Y
SPDR S&P Biotech ETF Experiences Big Outflow
NASDAQ · 10h ago
Weekly Report: what happened at ALPN last week (0429-0503)?
Weekly Report · 1d ago
Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?
NASDAQ · 04/30 09:36
Weekly Report: what happened at ALPN last week (0422-0426)?
Weekly Report · 04/29 12:00
Wall Street Breakfast: The Week Ahead
It's a big week on the macro front with the Federal Reserve meeting and jobs report. In corporate earnings, major reports are due from Apple and Amazon. Viking Holdings will launch its IPO. The most over-bought and over-sold stocks in the S&P 500.
Seeking Alpha · 04/28 11:22
Catalyst Watch: Apple earnings, Viking IPO, Chinese EV deliveries and Russell indices' Rank Day
Seeking Alpha's Catalyst Watch includes a look at next week's key events. The Russell indices' ranking day will be used for the reconstitution of the firm's U.S. Indexes on April 26, 2024. Shares of Tesla will update monthly deliveries of electric vehicles in China. Apple's earnings and Viking's IPO are the focus of the week.
Seeking Alpha · 04/26 19:00
$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management Drugs
Vertex Pharmaceuticals Inc’s blockbuster drug Trikafta for cystic fibrosis is expected to reach $10 billion in annual sales next year. The company is also developing non-opioid painkillers. Vertex's challenge lies in replicating its success in CF treatment across other diseases.
Benzinga · 04/26 18:34
ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN
Former Attorney General of Louisiana Charles C. Foti, Jr. And the law firm of Kahn Swick & Foti are investigating the proposed sale of Alpine Immune Sciences, Inc. To Vertex Pharmaceuticals. Under the terms of the proposed transaction, shareholders of Alpine will receive $65.00 in cash for each share of Alpine. KSF is seeking to determine whether the consideration undervalues Alpine.
Barchart · 04/26 15:13
More
About ALPN
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which is engaged in discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The Company’s approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its ALPN-303 (povetacicept) is a dual antagonist of the B cell activating factor (BAFF) and a proliferation, inducing ligand (APRIL), cytokines, which play key roles in the pathogenesis of multiple autoimmune diseases via their contribution to the activation, differentiation and/or survival of B cells, particularly antibody-secreting cells, as well as T cells and innate immune cells. Its ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator (ICOS), and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Webull offers Alpine Immune Sciences Inc stock information, including NASDAQ: ALPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALPN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALPN stock methods without spending real money on the virtual paper trading platform.